Artemis Medicare Services Limited has informed the Exchange regarding Outcome of Board Meeting held on August 5, 2025
ARTEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts more than Nifty Microcap 250 and in line with its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Artemis Medicare Services reported its Q1 FY26 (quarter ended June 30, 2025) unaudited financial results, approved by the Board on August 5, 2025. On a standalone basis, revenue from operations rose to Rs 24,979.86 lakhs from Rs 21,689.24 lakhs in Q1 FY25, a growth of about 15%. Profit after tax climbed to Rs 2,141.72 lakhs from Rs 1,691.66 lakhs, a healthy increase of roughly 27%, with basic EPS of Rs 1.36 versus Rs 1.16. Consolidated revenue stood at Rs 25,496.09 lakhs and consolidated PAT at Rs 2,119.75 lakhs. During the quarter, the company issued 13.30 lakh equity shares to the Managing Director under an ESOP plan and paid an advance deposit of Rs 54 crore related to a new MoU with Dr. Vidyasagar Kaushalya Devi Memorial Health Centre for a future Medical Services Agreement. The statutory auditor T R Chadha & Co LLP issued an unmodified review conclusion on both standalone and consolidated results.
Strong profit growth and steady revenue expansion suggest positive operating momentum for shareholders, though revenue growth was moderate rather than exceptional. The new MoU and Rs 54 crore advance indicate possible expansion but also tied-up capital that investors should watch for future returns.